Disclosure Plus

CoAsia CM Decides on 5-for-1 Stock Consolidation

Park Sun-Yeop
2026-06-26 13:32:17
[Edaily Reporter Park Sun-Yeop ] CoAsia CM(196450)announced on the 26th that it has decided to conduct a stock consolidation, changing the par value per share from 1,000 won to 5,000 won.
As a result of this stock consolidation, the total number of issued shares will decrease from 45,319,582 common shares to 9,063,916.
The company explained that the purpose of the stock consolidation is “to stabilize the stock price and enhance corporate value by maintaining an appropriate number of shares in circulation.”
This stock consolidation is not a capital reduction that decreases the company’s capital; rather, it is a stock consolidation method that preserves corporate value. Fractional shares (less than one share) will be settled in cash based on the closing price on the first day of trading of the new shares.
The stock consolidation proposal will be submitted to the Extraordinary General Meeting of Shareholders on August 6. The effective date for the new shares is August 11, and trading is scheduled to be suspended from August 7 through August 27. The new shares are scheduled to be listed on August 28.

Economy

Corporation

IT·Science

Economy

"Why Should I Buy That Apartment for You?"... Will It Take 30 Years for Gen Z and Millennials to Buy a Home in Seoul?

(Photo: Blind) One of the concerns facing the Lee Jae-myung administration is the decline in support among young people. According to Gallup Korea’s presidential job approval ratings, the approval…
2026-10-04 12:00:03

Corporation

[Exclusive] BrainOn’s ‘Seracue’ Notified of Suspension of Transactions by Major Clients… ‘On Track to Be Ousted from the Industry’

“Cera-Q,” a product by BrainOn Co., Ltd., which was distributed under false pretenses—passing off ingredients not recognized as having functional benefits by the Ministry of Food and Drug Safety (MFDS…
2026-10-05 08:01:04

IT·Science

Roche’s Choice: HanmiPharm’s New Obesity Drug; Vice President Choi In-young: “We Wanted to Lose Fat and Gain Muscle”

Lose fat while preserving muscle. As Roche has discontinued emugrovat—a candidate it was developing to counteract muscle loss during obesity treatment—the role of “HM17321,” a technology licensed by H…
2026-10-05 07:16:02